Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.

@article{Lee2003LosartanAE,
  title={Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.},
  author={Craig R. Lee and John A. Pieper and Alan L. Hinderliter and Joyce A. Blaisdell and Joyce A. Goldstein},
  journal={Pharmacotherapy},
  year={2003},
  volume={23 6},
  pages={720-5}
}
STUDY OBJECTIVE To determine if differences in the pharmacokinetics of losartan and its pharmacologically active E3174 metabolite exist among individuals expressing the cytochrome P450 (CYP) 2C9*1/*1, *1/*2, and *1/*3 genotypes. DESIGN Single-dose pharmacokinetic study. SETTING University general clinical research center. SUBJECTS Fifteen healthy volunteers, five from each genotype: CYP2C9*1/*1, *1/*2, and *1/*3. INTERVENTION A single oral dose of losartan 50 mg. MEASUREMENTS AND MAIN… CONTINUE READING

From This Paper

Topics from this paper.

Similar Papers

Loading similar papers…